Kohlberg Kravis Roberts & Co. L.P. Bridge Bio Pharma, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $2.53 Billion
- Q2 2025
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 13,260,971 shares of BBIO stock, worth $651 Million. This represents 22.63% of its overall portfolio holdings.
Number of Shares
13,260,971
Previous 19,260,971
31.15%
Holding current value
$651 Million
Previous $666 Million
14.0%
% of portfolio
22.63%
Previous 30.7%
Shares
6 transactions
Others Institutions Holding BBIO
# of Institutions
406Shares Held
188MCall Options Held
11.3MPut Options Held
2.2M-
Viking Global Investors LP18.6MShares$911 Million2.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$809 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$611 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X09.28MShares$455 Million0.21% of portfolio
-
Farallon Capital Management LLC San Francisco, CA7.9MShares$388 Million1.53% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $7.28B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...